Retroviral expression of leukemogenic oncogenes in the murine hematopoietic system is essential but not sufficient to induce acute leukemia. Proviral integration-mediated elevated expression of the meningioma 1 (MN1) oncogene suggested MN1 acting as cooperating event in mixed-lineage leukemia 1 (MLL) and eleven nineteen leukemia (ENL)-induced murine leukemia. Indeed, co-expression of MN1 with MLL-ENL enhanced transformation in vivo, and resulted in a significantly reduced latency for induction of an aggressive acute leukemia when compared with MN1 or MLL-ENL alone. In addition, coexpression of MN1 increased the granulocyte macrophage progenitor cell population with leukemia-initiating properties as shown in secondary transplantation experiments. Gene expression profiling experiments identified putative downstream MN1 targets, of which FMS-like tyrosine kinase 3 (FLT3) and CD34 were upregulated in both MN1-overexpressing murine leukemias and in pediatric acute leukemias with high MN1 levels. Interestingly, small interfering RNA (siRNA)-mediated MN1 knockdown resulted in cell cycle arrest and impaired clonogenic growth of human leukemia cell lines with high MN1 levels. Our work shows for the first time that high MN1 levels are important for the growth of leukemic cells, and that increased MN1 expression can synergize with MLL-ENL and probably other transforming fusion genes in leukemia induction through a distinct gene expression program that is able to expand the leukemia-initiating cell population.
Introduction
The meningioma 1 (MN1) gene was first identified as the target of a sporadic balanced chromosomal translocation in a patient with meningioma. 1 The absence of MN1 expression in the index patients has led to the suggestion that MN1 is a candidate tumor suppressor gene. Several studies have proposed that MN1 presumably exerts an effect as a transcriptional cofactor, most probably through interaction with other transcriptional regulators, such as p300/CREB-binding protein.
2 MN1 was first linked to human leukemia after the cloning of the balanced chromosomal translocation t(12;22)(p13;q12) in patients with acute myeloid leukemia (AML), myelodysplasia or chronic myelogenous leukemia. This translocation leads to the expression of an MN1-TEL fusion that consists of almost the entire open reading frame of MN1 fused with the DNA-binding moiety of TEL. 3 Expression of MN1-TEL in the mouse hematopoietic system by a conditional knock-in strategy resulted in the formation of T-cell lymphomas as well as AML after a long latency, suggesting that MN1-TEL, similar to MLL-X fusions, is essential but not sufficient to induce the disease. [4] [5] [6] Gene expression profiling studies of a large number of human leukemia samples showed that MN1 is deregulated in cases with alterations at 3q26 leading to ecotropic virus integration-1 (EVI1) overexpression. 7 In addition, elevated MN1 expression has been associated with the presence of inv16 leading to a core-binding factor-b/MYH11 fusion. 8 Recently, functional studies have shown that overexpression of MN1 alone is able to induce an AML phenotype in mice. 8, 9 Furthermore, high MN1 expression was shown to have negative prognostic effect in AML, especially in the absence of common karyotype abnormalities. 10, 11 Recurrent chromosomal translocations resulting in expression of oncogenic fusion genes are the hallmark of human leukemias. 12 Mixed-lineage leukemia 1 (MLL1) on 11q23 is one of the most frequently altered genes in human leukemia with MLL fusion genes involving over 50 partners or partial tandem duplications. 13, 14 Several studies have shown that a large number of MLL fusions as well as MLL-partial tandem duplications have in vitro and/or in vivo transforming activity. Indeed, transplantation of bone marrow cells retrovirally expressing various MLL fusions (such as MLL-AF9, MLL-ENL or MLL-GAS7) led to the induction of a lethal disease mimicking human acute leukemia. The clonal character as well as a latency period of 60 to 4200 days of the induced leukemia suggested that although MLL-X fusions are essential, they might not be fully sufficient for inducing a leukemic phenotype in vivo. [15] [16] [17] [18] [19] Elevated MN1 expression was not only associated with the presence of distinct genetic alterations (e.g. inv16, alterations of the EVI1 gene locus) in human leukemia, but the MN1 gene locus was also target of proviral integration site in mouse leukemia models induced by bone marrow reconstitution of retrovirally expressed oncogenes, such as mutant AML1 or NUP98-HOXD13. 20, 21 Searching for potentially cooperating events by cloning proviral integration sites in murine leukemia induced by retrovirally expressed MLL-ENL, we found increased MN1 expression in leukemic cells harboring an integration near the MN1 locus. These observations suggested that elevated MN1 levels might synergize in leukemia induction initiated by distinct genetic alterations such as MLL-ENL. By co-expression of MN1 and MLL-ENL in the murine hematopoietic system, we were able to show that overexpression of MN1 can exert an effect as a collaborative genetic hit in MLL-ENL-induced leukemia in vivo through expansion of the pool of leukemiainitiating cells. New putative MN1 target genes were identified and validated in mouse and human leukemias overexpressing MN1. For the first time, we show that small interfering RNA (siRNA)-mediated knockdown of MN1 impaired proliferation of human leukemic cells with abundant levels of MN1, suggesting that MN1 could represent a new therapeutic target.
Material and methods

Cell lines
The following human leukemia cell lines were analyzed: MV4;11, acute myeloid leukemia (MLL-AF4 þ , FMS-like tyrosine kinase 3 (FLT3)-ITD þ ), MOLM13, acute myeloid leukemia (MLL-AF9 þ ); EOL1, acute eosinophilic leukemia (MLL-partial tandem duplication); THP1, acute monocytic leukemia (MLL-AF9 þ ); KOCL44, acute lymphoblastic leukemia (MLL-ENL þ ), SEM, acute lymphoblastic leukemia (MLL-AF4 þ ), KOPN8, acute lymphoblastic leukemia (MLL-ENL þ ), RS4;11, acute lymphoblastic leukemia (MLL-AF4 þ ) and HL-60, acute myeloid leukemia. All cells were kept in RPMI-1640 with Glutamine (Invitrogen, Carlsbad, CA, USA) plus 10% fetal bovine serum and penicillin/streptomycin at 37 1C.
Construction of recombinant retroviral vectors
Full-length human 5 0 -FLAG-tagged MN1 complementary DNA (cDNA) was excised (SacI-HindIII) from pCMVTag2B-MN1 (a kind gift from Dr Paul MacDonald, Cleveland, OH) and transferred into the pSL1180 (SacI-SmaI) cloning vector and further subcloned into pMSCV-IRES/EYFP. The MLL-ENL cDNA (a kind gift from Dr Robert Slany, Erlangen, Germany) was subcloned from pMSCV-pgk/neo into pMSCV-IRES/EGFP (for single transductions) or pMSCVpgk/puro (for double transductions) using a unique EcoRI site. All expression plasmids were verified by extensive restriction digests, and by partial sequencing.
Bone marrow infections and transplantation
Bone marrow cells were harvested from 6-to 10-week-old (FVB/ N Â 129/S1)F1 mice 4 days after intraperitoneal injection of 5-fluorouracil 150 mg/kg (Sigma, St Louis, MO, USA), and were cultured for 24 h in RPMI-1640 supplemented with 10% fetal bovine serum, 10 ng/ml of human interleukin-6 (IL-6), 6 ng/ml of murine IL-3 and 100 ng/ml of murine stem cell factor (PeproTech EC, London, UK). HEK293T cells were transiently co-transfected with pMSCV retroviral vector and a packaging vector (pIK6), and virus containing supernatants were collected after 48 h and concentrated by 60 min of centrifugation at 14 000 r.p.m. at 4 1C. Retroviral infections were performed by spinoculation of the cells (2500 r.p.m. for 90 min at 30 1C) with retroviral supernatant on two consecutive days. 1 Â 10 6 transduced bone marrow cells were injected into the tail vein of lethally irradiated ( 60 Co, 950 rad) syngenic recipients. Transduction with two viruses (MLL-ENL in pMSCV-puro and MN1 in pMSCV-YFP) was performed sequentially: after transduction with the MLL-ENL-expressing virus, the cells were selected for 7 days before transduction with the MN1-encoding virus. For secondary transplantation, the limiting doses of leukemic blasts (from 5 Â 10 5 to 500) from primary mice were transplanted into sublethally irradiated (450 rad) recipients by tail vein injection.
Serial replating assay
10
4 transduced bone marrow cells were plated in 1 ml of methylcellulose culture (Stem Alpha.mIE, Stem Alpha, St Clement les Places, France) containing IL-3, IL-6 and murine stem cell factor. The number of colonies was counted after 7 days. Colonies were harvested, and 10 4 cells were replated in methylcellulose for four rounds.
Analysis of transplanted mice
After red cell lysis peripheral blood and bone marrow cells were counted and analyzed using a flow cytometer (Cyan II, Becton Dickinson, Franklin Lakes, NJ, USA), single-cell suspensions were stained with phycoerythrin, or allophycocyanin fluorochromes-labeled c-Kit, Sca1, Gr1, Mac1, B220 and CD34 monoclonal antibodies (all from Pharmingen, San Diego, CA, USA). Histopathological analysis of peripheral blood, bone marrow and hematopoietic organs were performed using standard procedures.
Southern blot analysis
Southern blot analysis was performed using standard protocols. 22 Clonality of the MSCV-MLL-ENL provirus was assessed using a 2.2 kb Hind III human MLL1 cDNA fragment as the hybridization probe. 23 The Mn1 locus-specific probe was generated using PCR and the primer sequences are available upon request.
Retroviral integration cloning by splinkerette PCR
Genomic DNA isolated from bone marrow or spleen cells of leukemic mice was digested with NlaIII or MseI for 12-16 h, and ligated to the splinkerette linker overnight. The nested PCR was performed by using splinkerette linker-specific primers and primers recognizing the long terminal repeat of pMSCV. 24, 25 Amplicons from the second PCR were separated on 2% agarose gel, purified by gel purification kit (Qiagen, Hilden, Germany) and subcloned into pCR 2.1-TOPO vector (Invitrogen) before sequencing, or directly sequenced by using the BigDye Terminator v3.1 chemistry and ABI 3130 DNA genetic analyzer (Applied Biosystems, Foster City, CA, USA). The obtained sequences were analyzed using BLAST against the mouse genome database of the National Center for Biotechnology Information.
siRNA knockdown experiments
The MN1-specific short hairpin RNA or scramble short hairpin RNA lentiviral plasmids (pLKO.1-puro) were purchased from Sigma (cat. no. 07310707MN). Lentiviral vector packaging was performed according to the calciumphosphate method. In brief, short hairpin RNA lentiviral plasmid was mixed with envelope plasmid pMD2G, packaging plasmid pMDLg/pRRE and Revexpression plasmid pRSV-Rev, and 0.5 M CaCl 2 was added. The mixture was added drop-wise to 2 Â BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) while vortexing at full speed. After 20 min of incubation, the precipitate was slowly added to the 293T cell monolayer. Lentiviral supernatants were harvested after 48 h by spinning at 2500 r.p.m. and filtering through 0.45 mm filter. Lentivirus were further concentrated by spinning through Vivaspin 20 concentrator (Sartorius Biolabs, Goettingen, Germany) at 4000 r.p.m. at 4 1C for 30 min, and stored at À80 1C.
Immunofluorescence
Cells were first fixed with 4% paraformaldehyde and then cytospin and immunolocalization were performed. Cells were permeabilized with 0.5% Triton X-100 in phosphate-buffered saline, treated with RNase and blocking was performed in 0.1% Tween-20/phosphate-buffered saline supplemented with 1% bovine serum albumin. The MN1 primary antibody (a kind gift from M Meesters and E Zwarthoff, Rotterdam, The Netherlands) was added for 1 h incubation at room temperature, and slides were then washed and incubated in the dark for 1 h with the Alexa Fluor 488 goat anti-mouse antibody (Invitrogen). Propidium iodide was used for nuclei staining. Slides were washed and mounted with Fluorsafe Reagent (Calbiochem, San Jose, CA, USA). Confocal microscopy was carried on a LSM 510 laser-scanning microscope (Zeiss, Oberkochen, Germany).
Fluorescence-activated cell sorting of GMPs
The isolated bone marrow cells were first stained with the lineage cocktail that contains antibodies specific for the following mouse lineage markers: biotinylated rat anti-mouse CD5, CD11b, CD45R/B220, Ly-6G (Gr-1) and Ter119 (MAGM209, R&D Systems, Minneapolis, MN, USA). Cells were then stained with a streptavidin Pacific Blue-conjugated (Invitrogen), a phycoerythrin-Cy5-conjugated anti-mouse IL-7Ra (A7R34, eBioscience, San Diego, CA , USA), a phycoerythrin-conjugated anti-mouse FcgRII/III (93, eBioscience), an Alexa Fluor 647-conjugated anti-mouse CD34 (RAM34, BD Biosciences, San Jose, CA, USA), an allophycocyaninconjugated anti-mouse c-Kit (2B8, BD Pharmigen) and a phycoerythrin-Cy7-conjugated anti-mouse Sca-1 (E13-161.7, BioLegend, San Diego, CA, USA) monoclonal antibody. Granulocyte macrophage progenitors (GMPs) were fluorescence-activated cell sorted as IL-7Ra
þ FcgRII/III high as described previously. 
Gene expression profiling
In three independent experiments, bone marrow cells were transduced with MSCV-MN1-IRES/EYFP or empty vector. At 72 h after transduction, EYFP-positive cells were sorted with fluorescence-activated cell sorting and RNA was isolated using ion-exchange chromatography with RNAmini (Qiagen) according to the manufacturer's protocol. cDNA target was synthesized, fragmented, biotin-labeled using the Whole Transcript Target Labeling and Control Reagents (Affymetrix, cat. no. 900652, Santa Clara, CA, USA) starting from 200 ng total RNA, according to the procedure described in the Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay Manual, Version 4. The cDNA was fragmented and the resulting fragments of approximately 40-70 nucleotides were monitored with the Bioanalyzer using the RNA Nano 6000 Chip (Agilent, Palo Alto, USA). The hybridization cocktail containing fragmented biotin-labeled target DNA at a final concentration of 25 ng/ml was transferred into GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix, cat.no. 901168) and incubated at 45 1C on a rotator in a hybridization oven 640 (Affymetrix) for 17 h at 60 r.p.m. The arrays were washed and stained on a Fluidics Station 450 (Affymetrix) using the Hybridisation Wash and Stain Kit using the Fluidics Procedure FS450_0007. The GeneChips were processed with an Affymetrix GeneChip Scanner 3000 7G. DAT image files of the microarrays were generated using Affymetrix GeneChip Command Console (AGCC, version 0.0.0.676). All statistical analyses were performed using GeneSpring GX software (Agilent). Genes were considered as significant whenever the fold change was superior to 1.5 and the P-value of o0.05. The data discussed in this publication have been deposited in the Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo/) of the National Center for Biotechnology Information and will be accessible through accession number GSE13189.
Patient samples
Expression of MN1 and putative downstream targets were measured in a panel of childhood acute leukemia bone marrow samples. Under informed consent by the guardians, 21 children diagnosed with acute lymphoblastic leukemia (ALL) and 6 with AML, according to the conventional FAB (French American British) and immunological criteria, were included. In all, 8 patients who were diagnosed of ALL were o1 year of age. On the basis of the immunophenotype, 15 patients were classified as B-cell precursor ALL, and 6 as T-ALL. Chromosome suspensions were used for cytogenetic and fluorescence in situ hybridization analyses. All infant leukemia samples harbored 11q23 alterations. Among the B-cell ALL patients were two patients with t(1;19) and one patient with t(12;21). One AML patient was positive for t (8;21) . For all samples, mononuclear cells were routinely isolated using Ficoll-Hypaque (Pharmacia-LKB, Uppsala, Sweden) density gradient centrifugation (bone marrow mononuclear cells) and then RNA isolated. All samples contained 490% of blasts as assessed by morphological and immunological criteria (not shown).
Results
While searching for potentially cooperating events by studying viral integration sites in murine leukemia induced by reconstitution with bone marrow cells that retrovirally expressed the MLL-ENL fusion, we found MN1 as an integration site flanking gene. As shown in Table 1 , we cloned 25 integrations from 10 mouse MLL-ENL leukemias. From leukemic blasts of three animals, only a single integration was found, whereas 5 others harbored 3 or 4 integrations. Southern blot analysis further confirmed the (oligo)-clonal nature of the disease and the provirus insertion adjacent to the Mn1 gene locus in one sample ('ME10') (Supplementary Figure 1) . Integration near the MN1 locus resulted in significant upregulation of its mRNA expression in the respective animal ( Figure 1a) . We therefore decided to study the effect of elevated MN1 expression in MLL-ENL-mediated leukemia. We first studied the transforming potential of elevated MN1 expression in primary mouse bone marrow cells. Retroviral expression of human MN1 resulted in blocked differentiation, aberrant self-renewal and growth advantage, as shown in serial replating assays in methylcellulose and in liquid cultures confirming previous observations 8, 9 (data not shown). This suggested that MN1 might functionally collaborate with the MLL-ENL fusion in the development of the acute leukemia phenotype. To experimentally address this hypothesis, we performed a series of bone marrow transplant experiments, in which we reconstituted lethally irradiated mice with bone marrow transduced with retrovirus expressing MLL-ENL, MN1 or both. For co-expression bone marrow cells were first transduced with the virus encoding MLL-ENL, followed shortly Roman numerals in ME mean different insertion sites identified from the same leukemic mouse.
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by a second transduction with the MN1-expressing virus. Analogous to previous studies, reconstitution with MLL-ENL (n ¼ 10) or with MN1 (n ¼ 8) expressing bone marrow in recipient mice led to the development of an acute leukemia phenotype after a median latency of 64 or 100 days, respectively (Figure 1b) . In contrast to MLL-ENL or MN1 alone, reconstitution of bone marrow co-transduced with virus encoding MLL-ENL and MN1 induced an aggressive AML-like disease after a significantly shorter median latency of 35 days after transplantation (Po0.001, log-rank test) (Figure 1b) . Leukemic blasts from than MLL-ENL (64 days) or MN1 alone (100 days). Significance of the differences in the latency periods between the corresponding groups was assessed using log-rank test (Po0.001). Co-expression of MLL-ENL with the empty vector (pMSCV-EGFP) did not change the latency. (c) Expression of cellular surface markers in leukemic blasts of murine acute leukemia induced by MLL-ENL, MN1 and MLL-ENL þ MN1 was analyzed using flow cytometry. MLL-ENL þ MN1-expressing leukemic blasts are characterized by high levels of Gr1/Mac1, c-kit and CD34. (d) Histological analysis showed the appearance of leukemic blasts in blood smears and extensive infiltration of leukemic blasts in multiple organs including liver, spleen, and skeletal muscle of mice co-transduced with MLL-ENL and MN1.
MLL-ENL þ MN1 disease expressed higher levels of c-Kit and CD34, but decreased levels of Gr1/Mac1 when compared with blasts from MLL-ENL-induced disease (Figure 1c) . The disease was characterized by very high white blood cell counts, the presence of leukemic blasts in peripheral blood and excessive infiltration in multiple organs such as bone marrow, spleen and liver ( Figure 1d and Supplementary Figure 2) . No change in the latency of the disease development was observed when bone marrow was co-transduced with MLL-ENL virus and an empty control virus (MSCV-EGFP ) (Figure 1b) . These in vivo observations suggested that MN1 could exert an effect as functional collaborator to MLL-ENL in murine leukemogenesis. Leukemic blasts overexpressing MLL-ENL and MN1 showed a significantly increased clonogenic growth potential in vitro when compared with leukemic cells induced by MLL-ENL or MN1 alone (Figure 2a) . To address the in vivo significance of Significance of the differences in latency period between the two groups of mice was assessed using log-rank test (Po0.01).
this observation, we performed a series of secondary transplantation experiments using flow-sorted EGFP þ or EYFP þ cells. As shown in Figure 2b , transplantation of 5 Â 10 5 MLL-ENL leukemic blasts into sublethally irradiated recipients resulted in AML after a median latency of 37 days. In contrast, transplantation of the same number of MLL-ENL þ MN1 leukemic cells resulted in AML after a significantly reduced latency (20 days, Po0.01, log-rank test). Further transplantations of dilutions of leukemic blasts showed that in contrast to MLL-ENL þ MN1 leukemia, 2000 MLL-ENL blasts were not sufficient to induce the disease in all the recipients. These experiments provided strong evidence that MN1 could functionally collaborate with MLL-ENL and suggested that MN1 overexpression might lead to expansion of a leukemia-initiating cell population.
Previous studied suggested that MLL fusion genes not only transform hematopoietic stem cells, but are also able to block differentiation and to provide aberrant self-renewal to committed hematopoietic progenitor cells, including GMPs, common myeloid progenitors CMP and/or common lymphoid progenitors. [15] [16] [17] 26 The significantly shorter latency in conjunction with a more immature, 'stem-cell like' phenotype leukemia suggested that overexpression of MN1 might lead to an expansion of the leukemic progenitor population hit by the MLL fusion gene. It is worth noting that in normal bone marrow the highest levels of MN1 expression were found in GMPs, which are amplified in several MLL-mediated transformations and might include the leukemia-initiating cells. 8, 15, 16 Therefore, we first compared the GMP populations in leukemic mice induced by MLL-ENL, MN1 or MLL-ENL þ MN1. As shown in Figure 2c , leukemias induced by MN1 and MLL-ENL þ MN1 were characterized by a significant expansion of the GMP population, and co-expression of MN1 with MLL-ENL increased the frequency of GMPs as 20 times more than MLL-ENL.
To test the possibility of an increase in leukemia-initiating GMPs in leukemic mice expressing MLL-ENL þ MN1, we transplanted identical numbers of flow-sorted GMPs into sublethally irradiated hosts. As shown in Figure 2d , transfer of 1000 GMPs from MN1 þ MLL-ENL leukemia reproduced the leukemic phenotype in all recipients after a median latency of 35 days. In contrast, an identical number of GMPs from MLL-ENL leukemia reproduced the disease only after a significantly prolonged latency period of 47 days (Po0.01, log-rank test). These experiments strongly support the idea of functional collaboration of MN1 with MLL-ENL at the leukemic GMP cell population level.
As MN1 has been proposed to exert an effect primarily as a transcriptional co-regulator in hematopoietic cells, we sought to obtain some insights about the MN1-regulated oncogenic gene expression program. 2 Thus, we compared the gene expression profiles of primary murine bone marrow cells overexpressing MN1 (MSCV-MN1-IRES/EYFP) with cells transduced with a control vector (MSCV-IRES/EYFP) using oligonucleotide arrays. As shown in Supplementary Table 2, transient overexpression of MN1 resulted in X1.5-fold upregulation of 831 genes and downregulation of 268 genes (Po0.05). As we asked for putative targets that might be involved in the leukemogenic activity of MN1, we selected genes that were more than twofold upregulated and previously functionally linked to malignant hematopoiesis and validated their expression levels using quantitative reverse transcriptase PCR analysis. DLK1, FLT3, CD34, ANGPT2, MAP2K1IP1, HLF, PRNP and MEIS1 were expressed at higher levels, and LIF and CRISP1 at lower levels in MN1-expressing cells when compared with mock-transduced mouse bone marrow (data not shown). We next determined the expression levels of these genes in blasts from mouse leukemias induced by MN1, MLL-ENL or co-expression of MLL-ENL and MN1. In most murine samples, elevated expression levels of DLK1, CD34, FLT3 and HLF was significantly associated with the presence of elevated expression of MN1 (Figure 3a) .
To validate these putative MN1 target genes in human leukemia, we compared their expression in a set of pediatric acute leukemia cases (including 7 B-ALL, 6 AML, 8 infant leukemias and 6 T-ALL) with elevated expression of MN1 versus those with low or absent MN1 expression (as found in normal bone marrow). High MN1 levels were found in B-cell ALL and cases of infant leukemias (Figure 3b) . We found significantly higher expression levels of CD34 (P ¼ 0.002) and FLT3 (P ¼ 0.03) in pediatric leukemia cases with significantly elevated MN1 levels than in cases with low or undetectable MN1 levels. Expression of DLK1 and HLF1 correlated with MN1 in some cases, but was not significant as a cohort (data not shown). In contrast to the murine samples (Figure 3a) , no association of MEIS1 expression with elevated MN1 levels could be observed.
Although elevated MN1 expression has been reported to provide negative prognostic information in adult AML cases, 10,11 the contribution of MN1 to the biology of any leukemic cell clone remained unclear. To functionally study the role of MN1 in a human leukemia, we first determined MN1 expression levels in a panel of acute leukemia cell lines (HL60, MV4;11, MOLM13, KOCL44, RS4;11, SEM, KOPN8, EOL-1 and THP1). As shown in Figure 4a , MN1 expression was detected in some cell lines, such as THP1, MOLM13, KOCL44 and RS4;11, but not in all cell lines harboring MLL fusion genes. Findings on the mRNA level were also reflected on the protein levels as shown by immunofluorescent staining of MN1 in MOLM13 versus SEM cells (Figure 4b) . To study the role of elevated MN1 expression for maintenance of the malignant cell phenotype, we transduced the cells with a lentivirus expressing either MN1-specific or scramble siRNAs. A series of control experiments showed that the four cell lines of the panel (HL60, MOLM13, RS4;11 and THP1) could be efficiently transduced (not shown). Expression of MN1 siRNAs resulted in a reduction of MN1 expression of 450% in HL60, MOLM13 and THP1 and 25-30% reduction in RS4;11 ( Figure 5a ). RNA interference-mediated knockdown of MN1 expression also resulted in a significant decrease of clonogenic growth (in methylcellulose) of THP1 and MOLM13 and to a lesser extent of RS4;11 ( Figure 5b) . Similarly, impaired growth potential of the cell lines expressing MN1 siRNAs was also observed in liquid cultures (Figure 5c ). The growth of HL-60 cells that express very low levels of MN1 was not affected by MN1 knockdown. Cell cycle analysis of THP1 and MOLM13 cells showed that MN1 knockdown led to a significant increase of cells in G 0 /G 1 associated with a lower number of cells in G 2 /M and S phase (Figure 5d ). The observed reduced growth rate was not related to an increase of apoptotic cell death (Supplementary Figure 3) . Interestingly, siRNAmediated knockdown of MN1 expression in THP1 cells was associated with reduced expression of the proposed MN1 target genes CD34 and FLT3, but not with MEIS1 expression, suggesting that CD34 and FLT3 might also be important mediators of MN1 activity in human hematopoietic cells (Supplementary Figure 4) . Taken together, these results showed for the first time that increased MN1 expression provides a positive growth signal to human leukemic cells, and functionally cooperates with a leukemogenic fusion oncogene through a genetic program that results in expansion of the leukemiainitiating cells. Quantitative RT-PCR analysis of expression of selected targets in pediatric leukemia cases with high or low levels of MN1 expression, or categorized into different subgroups of pediatric leukemia including B-ALL (n ¼ 7), infant leukemia (n ¼ 8), AML (n ¼ 6) and T-ALL (n ¼ 6). The expression levels of target genes were normalized to GAPDH, and given as DC t value relative to healthy controls (bone marrow). Dots represent mean value of duplicate for each patient sample and lines represent median levels of patient groups. The statistic analysis was performed using two-tailed t-test.
Discussion
Several studies have suggested that retroviral expression of MLL fusion genes in the murine hematopoietic system is necessary but rather not sufficient to induce an acute leukemia that recapitulates the human disease in many aspects. [14] [15] [16] [17] [18] [19] As our initial screens for structural aberrations (not shown) did not revealed any aberrations, we focused on proviral integration sites as potential cooperating events in 10 mice with MLL-ENLinduced acute leukemia. We were able to clone and validate 25 integrations in two independent experiments. It has been previously shown that mouse leukemia genes identified by retroviral insertion mutagenesis are more frequently differentially expressed in human acute leukemia than randomly selected genes or genes located more distantly from a provirus integration. 27, 28 Interestingly, several genes flanking the integration sites, such as SOCS1, JARID2, PTPRE, HSP90, GADD45, MGAT5, PP2R5C or MN1, have been previously linked to carcinogenesis (Table 1) . [29] [30] [31] [32] [33] The integration near the MN1 locus resulted in significantly increased levels of mRNA expression (Figure 1a) . Interestingly, the MN1 gene locus has been previously reported as a recurrent integration site in mouse models of human hematological malignancies induced by retroviral oncogene expression such as NUP98-HOXD13 or mutated AML1. 20, 21 Several studies suggested potential new functional links between MLL, core-binding factor and EVI1. EVI1 seems to be a downstream target in MLL-ENL and NUP98-HOX-mediated transformation. [34] [35] [36] In addition, direct interactions between MLL and AML1 seem to provide epigenetic regulation of gene expression in leukemic cells. 37 Although the exact molecular mechanisms remain to be elucidated, a positive role of MN1 in a putative pathway involving core-binding factor and EVI1 blocking differentiation and providing aberrant selfrenewal could explain why a clone with integration-mediated elevated MN1 expression would be selected in the presence of MLL-ENL.
As MN1 has in vitro and in vivo leukemogenic potential in the murine system 8, 9 ( Figure 1 ), retroviral integration-mediated MN1 overexpression in MLL-ENL-induced leukemia suggested a functional cooperation. Indeed, co-expression of MN1 with MLL-ENL resulted in the induction of an aggressive AML-like phenotype after a significantly reduced latency period (Figure 1 ). Previous studies have proposed that in addition to hematopoietic stem cells, committed progenitor cells such as common myeloid or lymphoid progenitors (common myeloid progenitors and common lymphoid progenitors) or even GMPs can also be targets of MLL-ENL, MLL-AF9 or MOZ-TIF2 transformation. 15, 16, 26, 38 Interestingly, in normal mice the highest levels of MN1 were found in GMPs. 8 Detailed comparison of the MLL-ENL-induced leukemia with the disease induced by expression of MLL-ENL and MN1 suggests that co-expression could lead to an expansion of the GMP population. Increased clonogenic activity of these cells further suggests that MN1 also regulates genes implicated in self-renewal. Accelerated induction of a leukemic phenotype in secondary transplants further supports the idea that GMPs represent a prominent disease-initiating cell pool (also often referred as leukemic stem cells) in MLL-ENL þ MN1 leukemia. Indeed, transplantation of sorted GMP cells from MLL-ENL and MLL-ENL þ MN1 leukemias into secondary recipients fully supported this idea (Figure 2d ). Further studies are needed to determine whether elevated MN1 levels would also increase the pool of leukemia-initiating cells in leukemias harboring inv16, or alterations of EVI1 that are often associated with MN1 overexpression.
In adult de novo AML with no detectable cytogenetic abnormalities, MN1 expression was associated with poor response to therapy, a higher disease relapse rate and shorter overall survival. 10, 11 These clinical observations as well as our experimental work suggest that elevated MN1 expression might be a general signature for an expanded leukemic stem cell pool. However, the nature of the disease-initiating stem cell in MLL fusion-induced murine leukemia is still a matter of debate: the expression of Gr1/Mac1 þ and c-Kit þ covering 25% of the blasts as well as lineage-negative (o1% of leukemic blasts) leukemic-hematopoietic stem cells, L-GMPs or L-common lymphoid progenitors (CLPs) that have been proposed to exert an effect as leukemic stem cells. [15] [16] [17] 26 However, independent of the chosen phenotypic markers, we observed a significant increase in potential leukemic stem cell pool when MN1 was co-expressed with MLL-ENL, as illustrated by secondary transplantation experiments (Figure 2) . Interestingly, transient and stable expression of MN1 was associated with increased CD34 expression (Figure 3) . Similarly, gene expression profiling of cytogenetically normal adult AML cases also very recently revealed an association between MN1 and CD34 expression levels.
11 CD34 is a well-characterized marker of early hematopoietic progenitor cells. 39 We revealed, for the first time, that a significant correlation of MN1 expression with CD34 levels was not only observed in the mouse leukemia model but also in a small cohort of primary samples from pediatric patients with B-cell ALL or infant leukemia (Figure 3 ). These observations are currently being validated in a larger cohort of pediatric acute leukemia patients.
Our results suggest a functional cooperation of MN1 with MLL-ENL leukemogenesis. It is worth noting that not all studied MLL fusion-positive human leukemia cell lines expressed elevated MN1 levels (Figure 4 ). In addition, our own and other researchers' gene expression profiling studies of experimental models of MLL fusion-induced leukemia never revealed MN1 as being a primary upregulated target 17, 26 (T Liu, D Jankovic, J Schwaller et al, unpublished observation). This raised the possibility that the MN1 expression status in a leukemic blast might be dependent on the maturation grade of the cell that was initially targeted by the MLL fusion and/or on a currently unknown mechanism that would maintain the MN1 levels high. Interestingly, an unusual methylation pattern of the MN1 promoter region was recently reported, suggesting that epigenetic mechanisms might be needed to sustain the elevated MN1 expression levels in cell transformed by oncogenic MLL fusion genes. 40 Forced siRNA-mediated downregulation of MN1 expression in cells that overexpress MN1 impaired growth in methylcellulose (colony formation) as well as in liquid culture. MN1 knockdown was associated with cell cycle arrest in G 0 /G 1 phase ( Figure 5 ). These results show, for the first time, that aberrant MN1 expression could be an important factor for proliferation of leukemic cells. As leukemic and normal hematopoietic cells expressing normal levels of MN1 were not affected by siRNAmediated knockdown, selective inhibition of MN1 in leukemiainitiating cells might be possible without affecting normal tissue. Currently, ongoing structure-function studies as well as protein interaction screens to search for critical domains for the leukemogenic activity of MN1 will provide new insights for future therapeutic targeting of the aberrant MN1 activity.
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